Pipeline

Xenexus Pharmaceuticals is building a pipeline of small molecule therapeutics based on drug repurposing. They offer the prospect of multi-target drugs with broad applicability across a range of complex diseases. The portfolio includes the following projects.

XEN-101 is for the treatment and prevention of Alzheimer's disease. The drug has demonstrated a good safety profile during many years of clinical use in other indications.

XEN-102 is a treatment for Alzheimer's disease based on the discovery of a new target.

XEN-103 is under development for stimulating liver regeneration following partial hepatectomy and liver transplantation in order to prevent postoperative liver failure.

XEN-104 is a treatment for the pain of acute gouty arthritis.

XEN-105 is a treatment for postoperative pain.

XEN-106 is a treatment for osteoarthritic pain with a much greater safety profile than nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors.

Strategy

The company's strategy is to progress its drug candidates into early clinical trials and then to out license to a large partner for onward development and commercialisation.